AN2 Therapeutics Inc — Cash Flow (NASDAQ:ANTX)

Financials

Cash from operating activities -33.46 M-53.29 M-49.26 M-29.83 M -29.83 M Cash from investing activities -21.77 M-43.28 M54.59 M28.31 M 28.31 M Cash from financing activities 70.36 M84.99 M372 K113 K 113 K Free cash flow -33.46 M-53.29 M-49.26 M-29.83 M -29.83 M

Haberler

AN2 Therapeutics, Jefferies ile 80 milyon dolarlık anlaşma imzaladı

AN2 Therapeutics akciğer enfeksiyonu ilacı için faz 2 denemesini başlattı

AN2 Therapeutics Stock Cools Off After 90% Rally - AN2 Therapeutics (NASDAQ:ANTX)

AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action? - AN2 Therapeutics (NASDAQ:ANTX)

AN2 Therapeutics özel satışta 40 milyon dolar topladı

AN2 Therapeutics raises $40M in private placement

AN2 Therapeutics PV/n için epetraborole Faz 2 denemesi planlıyor

AN2 Therapeutics plans phase 2 trial of epetraborole in PV

AN2 Therapeutics, Sarah Williams’ı baş muhasebe yetkilisi olarak atadı

AN2 Therapeutics appoints Sarah Williams as principal accounting officer

FDA clears IND for epetraborole trial in mycobacterium abscessus

AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?